DGX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
DGX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Quest Diagnostics's accounts receivables for the quarter that ended in Mar. 2025 was $1,404 Mil.
Accounts receivable can be measured by Days Sales Outstanding. Quest Diagnostics's Days Sales Outstanding for the quarter that ended in Mar. 2025 was 48.31.
In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Quest Diagnostics's Net-Net Working Capital per share for the quarter that ended in Mar. 2025 was $-67.27.
The historical data trend for Quest Diagnostics's Accounts Receivable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Quest Diagnostics Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
Accounts Receivable | Get a 7-Day Free Trial |
![]() |
![]() |
1,520.00 | 1,438.00 | 1,195.00 | 1,210.00 | 1,304.00 |
Quest Diagnostics Quarterly Data | ||||||||||||||||||||
Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | Mar25 | |
Accounts Receivable | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
1,322.00 | 1,319.00 | 1,376.00 | 1,304.00 | 1,404.00 |
Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.
Quest Diagnostics's Days Sales Outstanding for the quarter that ended in Mar. 2025 is calculated as:
Days Sales Outstanding | |||||
= | Accounts Receivable | / | Revenue | * | Days in Period |
= | 1404 | / | 2652 | * | 91 |
= | 48.31 |
2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Quest Diagnostics's accounts receivable are only considered to be worth 75% of book value:
Quest Diagnostics's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2025 is calculated as:
Net-Net Working Capital Per Share | |||||||
= | (Cash And Cash Equivalents | + | 0.75 * Accounts Receivable | + | 0.5 * Total Inventories | - | Total Liabilities |
- | Preferred Stock | - | Minority Interest) | / | Shares Outstanding (EOP) | ||
= | (188 | + | 0.75 * 1404 | + | 0.5 * 189 | - | 8754 |
- | 0 | - | 114) | / | 111.978 | ||
= | -67.27 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.
If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.
Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.
Thank you for viewing the detailed overview of Quest Diagnostics's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.
J. E. Davis | officer: SVP, Operations | C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094 |
Karthik Kuppusamy | officer: SVP, Clinical Solutions | 500 PLAZA DRIVE, C/O QUEST DIAGNOSTICS INC, SECAUCUS NJ 07094 |
Michael E Prevoznik | officer: Corp VP, Legal & Compliance | C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094 |
Catherine T. Doherty | officer: SVP, Physician Services Bus. | C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094 |
Patrick Plewman | officer: SVP for Diagnostic Services | 500 PLAZA DRIVE, C/O QUEST DIAGNOSTICS INC, SECAUCUS NJ 07094 |
Mark E Delaney | officer: SVP & Chief Commercial Officer | 500 PLAZA DRIVE, C/O QUEST DIAGNOSTICS INC, SECAUCUS NJ 07094 |
Vicky B Gregg | director | 1 CAMERON HILL CIRCLE, CHATTANOOGA TN 37402 |
Michael J Deppe | officer: VP, Corp. Controller & CAO | 500 PLAZA DRIVE, C/O QUEST DIAGNOSTICS, SECAUCUS NJ 07094 |
Luis Diaz | director | C/O JOUNCE THERAPEUTICS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02138 |
Timothy M Ring | director | C/O C.R BARD INC, 730 CENTRAL AVE, MURRAY HILL NJ 07974 |
Mark A Gardner | officer: SVP of Molecular Gen & Oncol | 500 PLAZA DRIVE, C/O QUEST DIAGNOSTICS INC, SECAUCUS NJ 07094 |
Samer Abdul Samad | officer: Executive Vice President & CFO | 5200 ILLUMINA WAY, SAN DIEGO CA 92122 |
Stephen H Rusckowski | director, officer: President and CEO | C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094 |
Tracey Doi | director | C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094 |
Gail R Wilensky | director | C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094 |
From GuruFocus
By PRNewswire • 04-01-2025
By GuruFocus News • 02-13-2025
By GuruFocus News • 04-22-2025
By PRNewswire • 03-18-2025
By PRNewswire • 03-19-2025
By GuruFocus News • 03-21-2025
By GuruFocus News • 04-09-2025
By GuruFocus News • 04-02-2025
By GuruFocus News • 03-19-2025
By PRNewswire • 02-13-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.